| Literature DB >> 35637601 |
Hideomi Ichinokawa1, Kazuya Takamochi1, Mariko Fukui1, Aritoshi Hattori1, Takeshi Matsunaga1, Kenji Suzuki1.
Abstract
BACKGROUND: The initial surgery for lung cancer with interstitial lung disease (ILD) is often followed by passive treatment due to the surgery-induced deterioration in respiratory function, and only a few studies have summarized the findings associated with a second surgery for lung cancer patients with ILD.Entities:
Keywords: interstitial lung disease; lung cancer; postoperative complication; recurrence; second surgery
Mesh:
Year: 2022 PMID: 35637601 PMCID: PMC9284167 DOI: 10.1111/1759-7714.14481
Source DB: PubMed Journal: Thorac Cancer ISSN: 1759-7706 Impact factor: 3.223
FIGURE 1Patient distribution in this study
Clinicopathological comparison between the groups with and without second surgery
| Variables | Group A (surgery) ( | Group B (no surgery) ( |
|
|---|---|---|---|
| Age at first surgery [IQR] | 72 [68–76] | 71 [66–80] | 0.51 |
| Male sex | 28 (82%) | 11 (100%) | 0.13 |
| Preoperative comorbidity (without interstitial lung diseases) | 28 (82%) | 10 (91%) | 0.50 |
| Smoking pack‐years [IQR] | 46.5 [36–60] | 60.0 [46–100] | 0.053 |
| Initial pathological stage (I/II/III) | 20/10/4 | 5/5/1 | 0.44 |
| JACS risk score [IQR] | 7 [7–11] | 11 [7–11] | 0.14 |
| VC, L [IQR] | 3.40 [2.80–4.06] | 2.86 [2.14–3.07] | 0.022 |
| %VC, % [IQR] | 104.1 [92.3–119.1] | 80.6 [71.1–91.5] | 0.004 |
| FEV1.0, L [IQR] | 2.26 [1.98–2.71] | 1.43 [1.10–1.80] | 0.001 |
| FEV1.0%, % [IQR] | 69.7 [64.8–77.4] | 63.0 [42.4–72.2] | 0.008 |
| %FEV1.0, % [IQR] | 93.4 [83.0–102.3] | 75.2 [58.8–104.5] | 0.001 |
| %DLCO, % [IQR] | 47.0 [39.2–58.5] | 32.4 [27.6–44.0] | 0.010 |
Abbreviations: DLCO, diffusing capacity for carbon monoxide; FEV1.0, forced expiratory volume in 1 s; IQR, interquartile range; JACS, Japanese Association for Chest Surgery; VC, vital capacity.
Intraoperative features of the second surgical group (group A)
| Variables | Group A (surgery) ( |
|---|---|
| First surgical procedure | |
| Wide‐wedge resection | 4 (12%) |
| Segmentectomy | 4 (12%) |
| Lobectomy and more than lobectomy | 26 (76%) |
| Surgical site | |
| Same side Right → Right | 8 (24%) |
| Left → Left | 3 (9%) |
| The other side Right → Left | 15 (44%) |
| Left → Right | 8 (24%) |
| Second surgical procedure | |
| Wide‐wedge resection | 15 (44%) |
| Segmentectomy | 7 (21%) |
| Lobectomy and more than lobectomy | 12 (35%) |
| Mediastinal lymph node dissection | 10 (29%) |
| Length of operation, minutes [IQR] | 121 [82–166] |
| Blood loss, ml [IQR] | 10 [5–25] |
| Hospital stay, days [IQR] | 8 [7–13] |
| Postoperative complications | 9 (26%) |
| Prolonged pulmonary fistula | 5 (14%) |
| Acute exacerbation of interstitial lung disease | 2 (6%) |
| Wound infection | 2 (6%) |
| Home oxygen therapy | 7 (21%) |
| 30‐day mortality | 1 (3%) |
| 90‐day mortality | 0 (0%) |
Abbreviation: IQR, interquartile range.
FIGURE 2Prognosis after the first and second surgeries (group A)
FIGURE 3Prognosis of the second surgery (group A) and nonsurgery groups (group B)
Postoperative features of the second surgical group (group A)
| Variables | Group A (surgery) ( |
|---|---|
| Pathology (Ad/Sq/Others) | 19/12/3 |
| Pathological stage (I/II/III/stump recurrence) | 26/4/2/2 |
| Recurrence case | 12 (35%) |
| Local metastasis | 11 (32%) |
| Distant metastasis | 1 (3%) |
| Recurrence treatment | |
| Surgery | 2 (17%) |
| Radiotherapy | 4 (33%) |
| Best supportive care | 6 (50%) |
Abbreviations: Ad, adenocarcinoma; Sq, squamous cell carcinoma.
Difference in recurrence location depending on surgical procedure
| Variables | Lobectomy and more than lobectomy ( | Segmentectomy and wide‐wedge resection ( |
|---|---|---|
| Intrapulmonary recurrence | 3 (25%) | 3 (14%) |
| Mediastinal lymph node | 2 (17%) | 0 (0%) |
| Intrapulmonary recurrence and mediastinal lymph node | 1 (8%) | 0 (0%) |
| Stump recurrence | 0 (0%) | 2 (9%) |
| Bone | 1 (8%) | 0 (0%) |